Jorgen Winroth joins Sobi to lead Investor Relations

Jorgen Winroth has joined Sobi to lead the company's Investor Relations
activities. Jorgen has served as Director, Investor Relations for AstraZeneca
North America for the past sixteen years. Jorgen has also served as a consultant
providing strategic Investor Relations services to a number of Scandinavian
corporations including Hafslund Nycomed AS, AB SKF, and Huhtamaki Oy, and
previously as Vice President, Investor Relations at Pharmacia. Jorgen will be
based in New York.

Åsa Stenqvist, who has served as interim Head of Communications and Investor
Relations, will leave Sobi on November 16.

"We are very pleased to welcome Jorgen to Sobi. He brings extensive experience
in Investor Relations and will focus on increasing our level of service and on
building awareness of Sobi in the investment community. At the same time we want
to thank Åsa for her many contributions to Sobi and wish her good luck in the
future," says Geoffrey McDonough, CEO of Sobi.



For further information, please contact:
Åsa Stenqvist, Head of Communications and IR (Interim) at +46 8 697 21 88 or
Jorgen Winroth at jorgen.winroth@sobi.com.


About Sobi
Sobi is an international healthcare company dedicated to bringing innovative
therapies and services to improve the lives of rare disease patients. The
product portfolio is primarily focused on inflammation and genetic diseases,
with three late stage biological development projects within hemophilia and
neonatology. Sobi also markets more than 40 products for companies in the
specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion
and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 10 October 2012 at 2:00 p.m. CET.